SAN FRANCISCO /PRNewswire/ --
The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.
(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )
Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.
Browse full research report with TOC on "Migraine Drugs Market Analysis Report By Therapeutic Class (Triptans, CGRP-based Therapies, Ditans, Neurotoxins, NSAIDs), By Treatment, By Route of Administration, And Segment Forecasts, 2018 - 2025" at:https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market
Further Key Findings From the Report Suggest:
- Germany leads the European market, driven by rising disease prevalence, novel drug launches, and increase in R&D activities
- The acute migraine treatment market will be supported by rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
- Biohaven's rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
- Eli Lilly's Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
- Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
- Drugs with novel targets in early-phase development include AOBiome Therapeutics' AOB-203 (antibacterial), Winston Pharma's Dolorac (histamine H1 receptor antagonists), NeuroAxons' NXN-188 (combination of NOS inhibitor and a triptan), and Biohaven's BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.
Browse related reports by Grand View Research:
- Protein Expression Market - The global protein expression market size was estimated at USD 1.2 billion in 2016.
- Nanoparticles - Metal & Metal Oxides Market in Healthcare - The global nanoparticles - metal & metal oxides market in healthcare was estimated at USD 25.86 billion in 2016.
- Medical Foods Market - The global medical foods market size was valued at USD 12.3 billion in 2015 and is expected to grow with a CAGR of 6.9% over the forecast period.
- Biologics Market - The global biologics market size was valued at USD 276.6 billion in 2015.
Grand View Research has segmented the global migraine drugs market based on treatment, therapeutic class, route of administration, and country:
- Migraine Drugs Treatment Outlook (Revenue, USD Million, 2017 - 2025)
- Acute / Abortive Treatment
- Preventive/ Prophylactic Treatment
- Migraine Drugs Therapeutic Class Outlook (Revenue, USD Million, 2017 - 2025)
- Triptans
- Acetylcholine Inhibitors
- Ergot Alkaloids
- NSAIDs
- Ditans
- CGRP small molecule antagonists
- CGRP monoclonal antibodies
- Others
- Migraine Drugs Route of Administration Outlook (Revenue, USD Million, 2017 - 2025)
- Oral
- Injectables
- Others
- Migraine Drugs Country Outlook (Revenue, USD Million, 2017 - 2025)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
